Related Experiment Video

Updated: Aug 24, 2026

A Hepatocellular Cancer Patient-Derived Organoid Xenograft Model to Investigate Impact of Liver Regeneration on Tumor Growth
08:15

A Hepatocellular Cancer Patient-Derived Organoid Xenograft Model to Investigate Impact of Liver Regeneration on Tumor Growth

Published on: February 2, 2024

Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation

Victor I Machicao1, Murli Krishna, Hugo Bonatti

  • 1Division of Hepatology and Gastroenterology, Mayo Clinic, Jacksonville, FL 32216, USA.

Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
|April 27, 2004
PubMed

Insights

Allograft steatosis, or fatty liver, occurs similarly in hepatitis C (HCV) and non-HCV patients after liver transplantation (LT). Recipient body mass index (BMI) predicts steatosis severity in HCV patients.

Area of Science:

  • Hepatology
  • Transplantation immunology
  • Viral hepatitis

Background:

  • The natural history of allograft steatosis in hepatitis C (HCV)-infected patients post-liver transplantation (LT) requires further elucidation.
  • Understanding factors influencing allograft steatosis is crucial for managing post-transplant outcomes.

Purpose of the Study:

  • To investigate the relationship between allograft steatosis and HCV recurrence after LT.
  • To identify predictors of allograft steatosis in HCV-infected recipients.

Main Methods:

  • Retrospective analysis of liver transplant recipients from March 1998 to December 2001.
  • Histological scoring of explanted liver tissue and biopsies (1 week, 4 months, 12 months) for steatosis, fibrosis, and activity.
  • Comparison of allograft steatosis incidence and severity between HCV-infected and non-HCV-infected patients.

Main Results:

  • Allograft steatosis incidence was similar in HCV (40% at 4 months, 36% at 1 year) and non-HCV patients.
  • Higher donor age and recipient body mass index (BMI) at or after LT predicted increased allograft steatosis in HCV patients.
  • Allograft steatosis severity did not correlate with fibrosis or necroinflammatory scores.

Conclusions:

  • HCV and non-HCV patients exhibit similar high incidences of allograft steatosis post-LT.
  • Recipient BMI is a significant predictor of allograft steatosis severity in HCV-infected liver transplant recipients.
  • Allograft steatosis does not predict the severity of HCV recurrence within the first year post-LT.

Related Concept Videos

Liver Regeneration01:24

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...